Mr Zuerblis brings to ImClone more than 25 years of financial and operational management experience. Mr Zuerblis is best known within the biotechnology industry as a former CFO of Enzon Pharmaceuticals.
During his 11-year tenure as Enzon’s CFO, the company successfully transitioned from a small, royalty-based specialty pharmaceutical organization into a fully integrated biopharmaceutical company with significant revenues driven by five marketed products and substantial capabilities in research, development, manufacturing, sales and marketing.
John Johnson, CEO of ImClone, said: “We believe Ken will contribute substantially to ImClone’s efforts in becoming a fully-integrated global leader in cancer therapies as we continue to aggressively pursue initiatives to maximize our Erbitux franchise and further advance our robust pipeline of novel antibodies.”